Nexentis Technologies Inc. (NXTS)
NASDAQ: NXTS · Real-Time Price · USD
5.00
-0.20 (-3.85%)
At close: Jun 26, 2026, 4:00 PM EDT
4.619
-0.380 (-7.62%)
After-hours: Jun 26, 2026, 7:57 PM EDT
Nexentis Technologies Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
9
Market Cap
3.65M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 263.00K | -131.00K | -33.25% |
| Dec 31, 2022 | 394.00K | -44.14K | -10.07% |
| Dec 31, 2021 | 438.14K | 205.87K | 88.63% |
| Dec 31, 2020 | 232.27K | 56.45K | 32.11% |
| Dec 31, 2019 | 175.82K | -250.77K | -58.78% |
| Dec 31, 2018 | 426.59K | 82.66K | 24.04% |
| Dec 31, 2017 | 343.93K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Nutrien | 26.88B |
| The Mosaic Company | 12.43B |
| ICL Group | 7.41B |
| CF Industries Holdings | 7.41B |
| The Scotts Miracle-Gro Company | 3.47B |
| FMC Corporation | 3.43B |
| CVR Partners | 643.22M |
| American Vanguard | 522.88M |
NXTS News
- 5 days ago - Nexentis Technologies Inc trading halted, volatility trading pause - TheFly
- 5 days ago - Nexentis Technologies Inc trading resumes - TheFly
- 5 days ago - Nexentis Technologies Announces International AI Drug Discovery Initiative Between MitoCareX Bio and Boltz to Accelerate Novel SLC Small-Molecule Discovery - GlobeNewsWire
- 10 days ago - Nexentis: Subsidiary MitoCareX Bio Successfully Completed Broad Analysis of SLC Transport Proteins to Support Discovery of Hard-to-Treat Cancers and Metabolic Diseases - GlobeNewsWire
- 11 days ago - Nexentis Technologies Inc trading resumes - TheFly
- 11 days ago - Nexentis Technologies Inc trading halted, volatility trading pause - TheFly
- 5 weeks ago - Nexentis Technologies says MitoCareX Bio achieves drug discovery milestone - TheFly
- 5 weeks ago - Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development - GlobeNewsWire